A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Exclusion Criteria

• •Treatment with Omega-3 fatty acids or niacin or fibrates within 8 weeks of screening.
• •Patients with confirmed Familial Chylomicronemia Syndrome (FCS) with hyperlipoproteinemia (HLP) Type-I diagnosis or known to be homozygotes or compound heterozygotes for mutations in HLP Type I-causing genes (such as LPL, apoCII, CPIHBP1, or LMF1) prior to screening.
• •Pancreatitis within 3 months prior to screening.
• •Uncontrolled type 2 diabetes (T2DM) (as defined by an HbA1c value of ≥8.0% at screening)
• •BMI \> 40 or history of bariatric surgery.
• •Nephrotic syndrome, Type 1 diabetes, HIV, HCV or HBV positive.
• •Estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1.73m2